PubRank

Brian Wigdahl

Author PubWeight™ 80.74‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008 2.40
2 Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother 2004 1.50
3 In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 2006 1.37
4 Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 2011 1.29
5 HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog 2008 1.22
6 Antiviral potentials of medicinal plants. Virus Res 2007 1.22
7 Characterization of a nuclear export signal within the human T cell leukemia virus type I transactivator protein Tax. J Biol Chem 2003 1.20
8 Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation. J Cell Physiol 2002 1.17
9 Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology 2009 1.17
10 Immunological control of herpes simplex virus infections. J Neurovirol 2013 1.08
11 Comparative in vitro sensitivities of human immune cell lines, vaginal and cervical epithelial cell lines, and primary cells to candidate microbicides nonoxynol 9, C31G, and sodium dodecyl sulfate. Antimicrob Agents Chemother 2002 1.07
12 The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res 2011 1.07
13 Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1. Biomed Pharmacother 2005 1.04
14 Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother 2011 1.04
15 Comparative safety evaluation of the candidate vaginal microbicide C31G. Antimicrob Agents Chemother 2005 1.03
16 Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology 2003 1.01
17 Secretion of the human T cell leukemia virus type I transactivator protein tax. J Biol Chem 2005 0.98
18 Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol 2011 0.98
19 DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells. J Virol 2009 0.97
20 Differences in N-linked glycosylation between human surfactant protein-B variants of the C or T allele at the single-nucleotide polymorphism at position 1580: implications for disease. Biochem J 2003 0.95
21 Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G. Biomed Pharmacother 2005 0.95
22 Human T cell leukemia virus type I Tax activates CD40 gene expression via the NF-kappa B pathway. Virology 2005 0.95
23 Region-specific distribution of human immunodeficiency virus type 1 long terminal repeats containing specific configurations of CCAAT/enhancer-binding protein site II in brains derived from demented and nondemented patients. J Neurovirol 2004 0.94
24 Human immunodeficiency virus viral protein R as an extracellular protein in neuropathogenesis. Adv Virus Res 2011 0.94
25 Human T-cell leukemia virus type I Tax induces the expression of dendritic cell markers associated with maturation and activation. J Neurovirol 2004 0.93
26 A novel high throughput quantum dot-based fluorescence assay for quantitation of virus binding and attachment. J Virol Methods 2007 0.93
27 Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses. Antimicrob Agents Chemother 2010 0.92
28 Use of human antigen presenting cell gene array profiling to examine the effect of human T-cell leukemia virus type 1 Tax on primary human dendritic cells. J Neurovirol 2006 0.92
29 Global NeuroAIDS roundtable. J Neurovirol 2013 0.92
30 HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and adjacent regions is sequence-specific. Biomed Pharmacother 2003 0.91
31 Structural and functional evolution of human immunodeficiency virus type 1 long terminal repeat CCAAT/enhancer binding protein sites and their use as molecular markers for central nervous system disease progression. J Neurovirol 2003 0.90
32 PMA-induced differentiation of a bone marrow progenitor cell line activates HIV-1 LTR-driven transcription. DNA Cell Biol 2007 0.90
33 Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother 2010 0.89
34 Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol 2011 0.89
35 Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother 2008 0.89
36 Specific sequence configurations of HIV-1 LTR G/C box array result in altered recruitment of Sp isoforms and correlate with disease progression. J Neuroimmunol 2004 0.88
37 Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1. J Leukoc Biol 2007 0.88
38 Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Virol J 2012 0.88
39 HTLV-1 Tax nucleocytoplasmic shuttling, interaction with the secretory pathway, extracellular signaling, and implications for neurologic disease. J Biomed Sci 2005 0.88
40 High-affinity interaction between HIV-1 Vpr and specific sequences that span the C/EBP and adjacent NF-kappaB sites within the HIV-1 LTR correlate with HIV-1-associated dementia. DNA Cell Biol 2004 0.87
41 Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review. Am J Infect Dis 2009 0.86
42 CCAAT/enhancer-binding proteins modulate human T cell leukemia virus type 1 long terminal repeat activation. Virology 2006 0.86
43 Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Biomed Pharmacother 2010 0.86
44 Substance abuse, HIV-1 and hepatitis. Curr HIV Res 2012 0.85
45 Innate and adaptive factors regulating human immunodeficiency virus type 1 genomic activation. J Neuroimmune Pharmacol 2010 0.85
46 Impact of Tat Genetic Variation on HIV-1 Disease. Adv Virol 2012 0.85
47 Animal models of herpes simplex virus immunity and pathogenesis. J Neurovirol 2014 0.85
48 Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro. J Virol 2006 0.84
49 Role of resident CNS cell populations in HTLV-1-associated neuroinflammatory disease. Front Biosci (Landmark Ed) 2009 0.84
50 A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection. J Biomed Biotechnol 2010 0.84
51 Murine FLT3 ligand-derived dendritic cell-mediated early immune responses are critical to controlling cell-free human T cell leukemia virus type 1 infection. J Immunol 2010 0.84
52 Prolonged exposure to the candidate microbicide C31G differentially reduces cellular sensitivity to agent re-exposure. Biomed Pharmacother 2005 0.84
53 Induction of pro-inflammatory cytokines by human T-cell leukemia virus type-1 Tax protein as determined by multiplexed cytokine protein array analyses of human dendritic cells. Biomed Pharmacother 2007 0.83
54 Interaction of HTLV-1 Tax protein with calreticulin: implications for Tax nuclear export and secretion. Biomed Pharmacother 2007 0.83
55 Differentiation of xenografted human fetal lung parenchyma. Early Hum Dev 2007 0.83
56 Dendritic cells in autoimmune diseases and neuroinflammatory disorders. Front Biosci 2007 0.83
57 Transcriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathway. Biomed Pharmacother 2011 0.83
58 Regulation of human immunodeficiency virus type 1 gene expression and pathogenesis by CCAAT/enhancer binding proteins in cells of the monocyte/macrophage lineage. J Neurovirol 2002 0.82
59 Cocaine alters cytokine profiles in HIV-1-infected African American individuals in the DrexelMed HIV/AIDS genetic analysis cohort. J Acquir Immune Defic Syndr 2014 0.82
60 Identification of human T cell leukemia virus type 1 tax amino acid signals and cellular factors involved in secretion of the viral oncoprotein. J Biol Chem 2007 0.82
61 CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection. Future Microbiol 2009 0.82
62 Critical design features of phenyl carboxylate-containing polymer microbicides. Antimicrob Agents Chemother 2006 0.82
63 Mortality among HIV-Infected Patients in Resource Limited Settings: A Case Controlled Analysis of Inpatients at a Community Care Center. Am J Infect Dis 2009 0.82
64 AP-1-directed human T cell leukemia virus type 1 viral gene expression during monocytic differentiation. J Leukoc Biol 2006 0.82
65 Identification of binding sites for members of the CCAAT/enhancer binding protein transcription factor family in the simian immunodeficiency virus long terminal repeat. Biomed Pharmacother 2003 0.82
66 Extracellular HIV-1 viral protein R affects astrocytic glyceraldehyde 3-phosphate dehydrogenase activity and neuronal survival. J Neurovirol 2013 0.82
67 Impact of age on markers of HIV-1 disease. Future Virol 2013 0.82
68 Regulation of human T-cell leukemia virus type 1 gene expression by Sp1 and Sp3 interaction with TRE-1 repeat III. DNA Cell Biol 2006 0.82
69 Extracellular human immunodeficiency virus type 1 viral protein R causes reductions in astrocytic ATP and glutathione levels compromising the antioxidant reservoir. Virus Res 2012 0.81
70 Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1. Virology 2010 0.81
71 Depletion of dendritic cells enhances susceptibility to cell-free infection of human T cell leukemia virus type 1 in CD11c-diphtheria toxin receptor transgenic mice. J Immunol 2010 0.81
72 Epigenetics, drugs of abuse, and the retroviral promoter. J Neuroimmune Pharmacol 2013 0.80
73 C/EBP- and Tat-mediated activation of the HIV-1 LTR in CD34+ hematopoietic progenitor cells. Biomed Pharmacother 2003 0.80
74 Mediators of central nervous system damage during the progression of human T-cell leukemia type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2003 0.80
75 HIV-1 Latency and Eradication: Past, Present and Future. Curr HIV Res 2016 0.80
76 Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model. J Biomed Biotechnol 2011 0.79
77 Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother 2004 0.79
78 Structural and functional studies of CCAAT/enhancer binding sites within the human immunodeficiency virus type 1 subtype C LTR. Biomed Pharmacother 2010 0.78
79 Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety. BMC Pharmacol Toxicol 2012 0.78
80 Effects of highly active antiretroviral therapy on HIV-1-associated oral complications. Curr HIV Res 2007 0.77
81 A nipple shield delivery system for oral drug delivery to breastfeeding infants: microbicide delivery to inactivate HIV. Int J Pharm 2012 0.77
82 Macrophage colony stimulating factor regulation by nuclear factor kappa B: a relevant pathway in human immunodeficiency virus type 1 infected macrophages. DNA Cell Biol 2011 0.77
83 Biochemical analysis of human milk treated with sodium dodecyl sulfate, an alkyl sulfate microbicide that inactivates human immunodeficiency virus type 1. J Hum Lact 2006 0.77
84 Cellular phenotype impacts human immunodeficiency virus type 1 viral protein R subcellular localization. Virol J 2011 0.77
85 Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development. J Gen Virol 2012 0.77
86 Inactivation of HIV-1 in breast milk by treatment with the alkyl sulfate microbicide sodium dodecyl sulfate (SDS). Retrovirology 2005 0.77
87 Effect of μ-opioid agonist DAMGO on surface CXCR4 and HIV-1 replication in TF-1 human bone marrow progenitor cells. BMC Res Notes 2014 0.76
88 HIV-1 infection in a small animal human vaginal xenograft model. J Acquir Immune Defic Syndr 2003 0.75
89 Critical Review: Immunomodulation by Seminal Factors and Implications for Male-to-Female HIV-1 Transmission. J Acquir Immune Defic Syndr 2015 0.75